



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

May 23, 2022

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Sreet, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclose herewith the Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 for your information.

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 1 /2022-23

23rd May, 2022

Legal Update

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that FMC Corporation has filed a Suit against NATCO for a Process Patent # IN 298645 in the Delhi High Court today.

Patent IN 298645 covers a Process to prepare CHLORANTRANILIPROLE (CTPR) that is set to expire on December 6, 2025.

NATCO has submitted to the Court that its CTPR process does not infringe IN 298645 and that it will launch its CTPR product after August 13, 2022, when the CTPR product patent expires with non-infringing process. The next hearing date in this Suit is July 18, 2022.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer